Via practica 2/2022

GLP-1 receptor agonists in therapy of obesity

GLP-1 receptor agonists have significant position in therapy of type 2 diabetes mellitus. At present, some GLP-1 receptor agonists are approved and used also as drugs for therapy of obesity regardless of presence of diabetes mellitus. In antiobesitogenic effect of GLP-1 receptor agonists play role their central and periphery effects. Liraglutide 3,0 mg in clinical program SCALE proved efficacy and safety in therapy of obesity. Liraglutide 3,0 mg will be in clinical market in Slovakia from May 2022, fully paid by patient, prescribed by all doctors, without prescription limitation. It is administered subcutaneously once daily by prefilled injectable pen independent of food. To possible side effects of therapy with liraglutide belong gastrointestinal troubles, but they are usually mild and temporary.

Keywords: obesity, GLP-1 receptor agonists, liraglutide 3,0 mg